Abstract:Background: Patients with multiple sclerosis (MS) are at higher risk of having infections due to receiving disease modifying therapies. The current study was conducted among Iranian MS patients who had experienced at least one episode of COVID-19 infection in order to evaluate the effects of COVID-19 vaccination on symptoms of their infection. Data on demographic information, MS characteristics, COVID-19 infection details, and vaccination status were collected. Statistical analyses, were performed to evaluate the association between vaccination and symptoms of COVID-19 infection. Methods: This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients' who declared to be vaccinated was checked by their COVID-19 vaccination card. Results: A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (P-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, P-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, P-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39). Conclusion: COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination.

The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis

Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis

Association between human herpesviruses and multiple sclerosis: A systematic review and meta-analysis

The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis

Role of Viruses in the Pathogenesis of Multiple Sclerosis

Viral infections and multiple sclerosis

Multiple Sclerosis and health outcomes: an umbrella review of systematic reviews and meta-analyses

Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors

The effect of COVID-19 on Multiple Sclerosis relapse: A systematic review and meta-analysis

The interaction between Epstein–Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities

Association between cytomegalovirus infection and neurological disorders: A systematic review

Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment

Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review

The coincidence of multiple sclerosis and primary vasculitis; from the bench of pathology to the bedside of treatment: a systematic review of case reports

Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism

Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications

Influence of infection on exacerbations of multiple sclerosis

Evaluation of viral infection as an etiology of ME/CFS: a systematic review and meta-analysis

Toxoplasma gondii and multiple sclerosis: A systematic review and meta‐analysis

Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients